Contineum Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 14, 2025 and accepted by EDGAR at May 14, 2025, 20:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2025-01-01 to 2025-03-31 | $13.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | −$18.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2025-01-01 to 2025-03-31 | −$16.0m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | −$0.62 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$14.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-31 | $47.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-03-31 | $22.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $192.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $198.3m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $8.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $13.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $184.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-25-016835. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.